A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

Clinical trial NCT03398148 · COMPLETED

Trial details

NCT number: NCT03398148
Sponsor: AbbVie
Status: COMPLETED
Phase: Phase 2, Phase 3
Study type: INTERVENTIONAL

Ulcerative Colitis (UC)

Start date: 2018-03-07
Primary completion: 2022-11-09
Enrollment: 1558

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.